Hypothesis Records
Higher frequency of PEM crashes in pediatric ME/CFS patients will correlate with faster decline in RPI component biomarkers over 2 years, independent of baseline severity. Patients who experience fewer crashes will maintain higher RPI scores and have greater probability of recovery.
Adults with ME/CFS randomized to HRV-guided pacing will experience fewer PEM crashes and achieve better functional outcomes over 6 months compared to those using standard symptom-based pacing.
Patients who progress to ME/CFS will show a temporal transition from immune activation (early timepoints) to immune exhaustion (later timepoints), while recovered patients will show resolution of activation without exhaustion. The timing and rate of this transition will predict outcome.
Patients randomized to a “Brain First” sequence (LDA/LDN→Mestinon→peripheral support) show superior 6-month outcomes and faster cognitive improvement compared to “Mast Cell First” (mast cell stabilization first) or “Metabolic First” (metabolic supplementation first) sequences, due to removal of the neuroinflammatory barrier to recovery (Crosby, Kalantar, and DeRisi 2021).
Immune profiles at 4 weeks post-infection will predict 12-month ME/CFS status with >80% accuracy. Specific predictors will include:
- Impaired viral clearance: Persistent viral RNA/protein detection
- Immune dysregulation: Abnormal cytokine profiles, immune cell subset changes
- Early exhaustion markers: Elevated PD-1, CTLA-4 on T cells
- Metabolic dysfunction: Abnormal mitochondrial function, energy metabolites
- Autonomic dysfunction: Early signs of dysautonomia
A composite biomarker panel combining these measures will achieve higher predictive accuracy than any single marker.
Aggressive, comprehensive intervention initiated within 12 months of ME/CFS symptom onset can prevent the establishment of permanent pathological states and significantly increase recovery rates compared to standard incremental care. The earlier and more comprehensive the intervention, the greater the recovery probability.
Each documented infection in ME/CFS patients produces quantifiable, irreversible baseline functional decline. Early antiviral intervention (\(<\) 24 hours from symptom onset) significantly reduces the magnitude of post-infectious decline compared to delayed treatment. Strict infection prevention protocols slow baseline functional decline compared to standard hygiene practices (NIH ME/CFS Research Roadmap Working Group 2024).
Increasing TSPO-PET signal intensity correlates with PEM recovery time and functional decline. Patients with progressive PEM show significantly higher TSPO-PET signal than stable PEM patients. Low-dose naltrexone (LDN) treatment reduces TSPO-PET signal and slows PEM worsening (Crosby, Kalantar, and DeRisi 2021).
Pediatric ME/CFS patients will demonstrate preserved biological plasticity compared to adult patients, manifest as:
- Lower epigenetic age acceleration (more youthful methylation patterns relative to chronological age)
- Higher naive T cell proportions (greater immune reserve)
- Greater mitochondrial respiratory capacity
- Higher metabolic flexibility
- Greater autonomic adaptability (higher HRV)
- More diverse hematopoietic stem cell clonality
These differences will persist after controlling for disease duration and severity, indicating that age-related biology—not disease stage—underlies the recovery differential.
Patients who develop ME/CFS will show evidence of viral reservoir persistence (viral RNA/protein in gut tissue, immune cells, or other compartments) at 6 and 12 months, while recovered patients will show complete clearance. Reservoir presence will correlate with symptom severity and immune activation markers.
ME/CFS involves selective impairment of CNS-dependent and demand-responsive processes while autonomous peripheral processes remain preserved. Specifically:
- Hair/nail growth will be normal in ME/CFS patients, demonstrating preserved autonomous peripheral metabolism
- Brain FDG-PET hypometabolism will correlate with CNS symptoms (cognitive dysfunction, orthostatic intolerance)
- Two-day CPET will show functional decline despite normal resting muscle ATP levels
- Electrical muscle stimulation will produce greater force output than voluntary contraction (CNS bypass effect)
- Cerebral blood flow will decline during orthostatic challenge in 90%+ of patients
These differences will persist after controlling for systemic inflammatory markers and metabolic parameters, indicating CNS-specific dysfunction rather than global energy failure.
Treating sleep disorders in ME/CFS patients reduces the rate of PEM threshold decline through improved glymphatic clearance and reduced neuroinflammatory burden. Patients with newly treated sleep apnea or sleep disorders will show slower neuroinflammatory marker increase and slower functional decline over 12 months compared to matched untreated controls (Nakatomi et al. 2014).
Pediatric ME/CFS patients who achieve stable clinical response to OI medications for \(\geq\) 6 months will maintain \(\geq\) 70% of their improvement 3 months after gradual medication withdrawal, reflecting functional recalibration of autonomic systems rather than mere symptom suppression.
PEM recovery requires >24 hours for complete functional and molecular restoration in ME/CFS patients, with recovery duration correlating with baseline severity and molecular biomarker trajectories. (Certainty: 0.55)
Primary Hypothesis. ME/CFS patients will show incomplete recovery at 24 hours post-CPET, with incremental improvement at 48h and 72h, and full recovery only by 7 days. Healthy controls will show full recovery by 24 hours.
Secondary Hypotheses.
- Epigenetic changes (DNA methylation) will normalize by 48h in healthy controls but remain abnormal at 72h in ME/CFS patients
- Recovery duration will correlate with baseline severity (mild less than moderate less than severe)
- Specific molecular signatures (e.g., DNA methylation patterns, EV protein cargo) will predict time to recovery
- Bedbound patients will show the most prolonged recovery, possibly exceeding 7 days
Mild-moderate ME/CFS patients randomized to sports medicine-adapted periodization (with structured 7–14 day deload cycles every 4–6 weeks) will experience fewer crashes and greater functional stability over 6 months compared to standard flexible pacing.